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Dear Sirs,
With great interest, we read the short comment of Giovanni
Lucignani about infection imaging [1]. Here, commentaries
are given, derived from a literature search including
summaries of recently published articles. An important part
of the publication was dedicated to the labelling of living
bacteria with antimicrobial agents, mainly to the application
of radiolabelled antibiotic ciprofloxacin for the specific
detection of bacteria. Dr. Lucignani stated; “that the
approach with technetium-labelled ciprofloxacin showed
considerable promise in the preliminary studies but clinical
trials have shown limitations”.
Onthecontrary,mostpre-clinicalstudieshaveshownpoor
specificity of technetium-labelled ciprofloxacin for bacterial
infections [2–7] and vivid discussions related to this topic
took place [8–10, 17]. One of the most tested radiolabelled
ciprofloxacin is Infecton® (Draximage, Quebec, Canada).
This compound was evaluated in the International Atomic
Energy Agency (IAEA, Austria, Vienna) sponsored study
of more than 500 patients and specificity was claimed for
bacterial infections [11]. However, related to its specificity,
other studies showed contradicting results in pre-clinical
[2–7] and clinical settings as well [12]. Although it was
suggested that this was due to sub-optimal labeling
conditions and sample preparations, such statements could
be easily refuted by routine radiochemical analysis and
biodistribution studies in laboratory animals. More recently,
claims for Infecton® in its specificity for detecting of
bacterial infections in humans (depending on the discrep-
ancy between early and late imaging) was refuted as well
by Palestro et al., as his group conducted a Phase II trial
sponsored by Draximage, the manufacturer of Infecton®,
and they experienced that this tracer disappeared from sites
of infection as well as from inflammation with equal
rapidity [13]. As Infecton® shows detection of bacterial
infections with poor specificity and accuracy [14], this
group seriously considered that it is unlikely that radio-
labelled antibiotics will ever be a viable method for
imaging infection. Moreover, the recent press release from
Draximage clearly stated that formulation development of
Infecton® targeting orthopaedic indications has, to date, not
been successful and Draximage will allocate the resources
devoted to this product to other projects (http://www.
draxishealth.com/pdf/Draxis_Q3_PR_US_GAAP.pdf). These
findings are supported by two recent studies in which for
synthetic
18F-ciprofloxacin, no specific binding to bacteria
was observed [15] and poor retention of this tracer in
bacteria-infected tissues in patients [16]. These findings
raise concerns about the specificity of radiolabelled anti-
biotics, especially for Infecton®, for the detection of
bacterial infections. The issue of whether the uptake is not
more than a blood pool effect or the non-specific penetration
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e-mail: m.m.welling@lumc.nlof radiolabelled ciprofloxacin through membranes of
bacterial and mammalian cells as well may explain the
conflicting findings [17, 18]. The rapid introduction of
Infecton® in clinical settings may pointing out the necessity
of the support of pre-clinical data and the analysis of
radiochemical structure for any new radiochemical tracer
dedicated to the detection of bacterial infections in clinical
practice.
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